Hormonal
Liraglutide (a GLP-1 receptor agonist) significantly reduces the risk of major adverse cardiovascular events (MACE) and cardiovascular death in patients with type 2 diabetes and high cardiovascular risk.
If you have type 2 diabetes and are at high risk for heart problems (like existing heart disease or multiple risk factors), adding liraglutide to your standard care can significantly lower your risk of heart attack, stroke, and death from cardiovascular causes. It is taken as a daily injection. While it can cause stomach issues, the cardiovascular benefits are substantial for this high-risk group.
The primary outcome occurred in significantly fewer patients in the liraglutide group (608 of 4668 patients [13.0%]) than in the placebo group (694 of 4672 [14.9%]) (hazard ratio, 0.87; 95% confidence interval [CI], 0.78 to 0.97; P<0.001 for noninferiority; P = 0.01 for superiority). Fewer patients died from cardiovascular causes in the liraglutide group (219 patients [4.7%]) than in the placebo group (278 [6.0%]) (hazard ratio, 0.78; 95% CI, 0.66 to 0.93; P = 0.007).
Why this rating
Large-scale, multicenter, double-blind, placebo-controlled randomized clinical trial (LEADER) with 9340 patients.
Source
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al. · New England Journal of Medicine · 2016
DOI 10.1056/nejmoa1603827
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →